// App-Quantinova.ai

3315 : Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial

Researchers

Presenter

  • Gesine Bug

Principal Investigators

  • Andreas Burchert

  • Kroeger Nicolaus

  • Sabine Huenecke

  • Ulrich Duenzinger

  • Andrea Wolf

  • Peter Bader

  • Hubert Serve

  • Oliver G. Ottmann

Medical Centers

  • University Hospital Hamburg-Eppendorf, Interdisziplinaere Klinik und Poliklinik fur Stammzelltransplantation, Hamburg, Germany

  • Division for Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany

  • Department of Hematology/Oncology, Goethe-University Hospital Frankfurt, Frankfurt Am Main, Germany

  • Department of Hematology/Oncology, Goethe-University Hospital Frankfurt, Frankfurt Am Main, Germany

  • Dep. of Hematology/Oncology and Immunology, University Hospital Marburg, Marburg, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Graft-versus-host disease

  • Myelodysplastic Syndrome

  • Acute myelocytic leukemia

  • Deep vein thrombosis

  • Pulmonary embolism

  • Venous thrombosis

  • Diabetes

  • Ulcerative colitis

  • Syncope

  • Sepsis

  • Gastric antral vascular ectasia

Biomarkers

  • Cluster of Differentiation 25

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 4

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Ubiquitin A-52 Residue Ribosomal Protein Fusion Product 1

  • Regulatory T cells

Drug/Treatment

  • Panobinostat

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved